The identification of BRAF mutations in thyroid cancer has prognostic and therapeutic implications.
INTRODUCTION
Mutations along the mitogen-activated protein (MAP) kinase pathway, involving the BRAF, RAS, and RET genes, are common in thyroid cancers. 1 Mutations in these genes result in constitutive activation of the MAP kinase pathway, leading to the survival and growth of thyroid cancer. BRAF p.V600E mutations are common in patients with papillary thyroid carcinoma (PTC), occurring in approximately 40% to 70% of these individuals. [1] [2] [3] In addition, anaplastic thyroid carcinoma (ATC), frequently derived from PTC, can harbor BRAF p.V600E mutations in 25% to 48% of cases. 1, 4, 5 The identification of BRAF mutations in thyroid cancer has prognostic and therapeutic implications. BRAF p.V600E-mutated PTC cases have been linked to more aggressive behavior such as metastasis, extrathyroidal invasion, and increased disease recurrence, 6 particularly in association with coexisting mutations of PIK3CA, AKT1, or TP53 and TERT promoter mutations. [7] [8] [9] [10] [11] These patients also tend to have radioactive iodine-refractory disease. 12, 13 Targeted therapies using selective BRAF inhibitors (vemurafenib and dabrafenib), which are approved for the treatment of melanoma, have been studied in phase 2 clinical trials in patients with PTC and small basket trials for patients with ATC with tumors harboring BRAF p.V600E mutations. [14] [15] [16] [17] Fine-needle aspiration (FNA) plays an important role in the initial evaluation of thyroid nodules. Several studies have shown that ancillary studies such as molecular testing that capitalize on an expanding knowledge of the genomic landscape of thyroid carcinomas can be used as a complement to FNA cytology to guide the clinical management of patients with thyroid nodules and thyroid cancer. [18] [19] [20] [21] [22] [23] Similarly, in patients with advanced disease, FNAs allow for the documentation of disease recurrence while also allowing for tumor mutational analysis for possible adjuvant therapeutic options. 24, 25 Targeted therapy using BRAF inhibitors is considered based on the presence of the BRAF p.V600E mutation in individuals with aggressive thyroid carcinomas, such as ATC, for whom therapy options are limited. Although the gold standard for determining BRAF mutation status is molecular testing by sequencing, this test is relatively expensive and involves a higher turnaround time. Thus, in patients with ATC and advanced PTC, the ability to perform BRAF p.V600E by immunoperoxidase (IPOX) staining on FNA samples facilitates the rapid and efficient triaging patients to treatment options. Immunostaining using the monoclonal antibody against BRAF p.V600E (clone VE1) has been previously reported in thyroid FNA cell blocks and liquid-based cytology, although to our knowledge very limited literature is available regarding the feasibility and utility of immunostaining on cytology direct smears. [26] [27] [28] At the study institution, confirmation of the primary diagnosis or recurrence of thyroid carcinoma frequently is performed on cytologic direct smears using rapid on-site evaluation at the time of the FNA procedure. Therefore, the ability to perform BRAF p.V600E (clone VE1) IPOX on the FNA smears would help to provide prognostic targets in patients with aggressive thyroid cancers. In the current study, we performed BRAF p.V600E IPOX staining in thyroid carcinoma FNA smears and cell block sections to evaluate its feasibility and utility in different cytology specimen preparations.
MATERIALS AND METHODS
After institutional review board approval, the institutional pathology database was searched (January 2013-January 2018) for thyroid carcinoma FNA specimens for which there was available material from smears and cell block sections with a known BRAF p.V600E mutation status (positive or negative) by molecular testing using next-generation sequencing 29 and/or BRAF p.V600E immunostaining on a corresponding surgical specimen from the same patient. For the direct smears, previously Papanicolaoustained slides fixed in Carnoy solution were chosen for immunostaining. The regressive Papanicolaou staining method was performed manually using the following method: 10 dips in 95% alcohol, 10 dips in tap water, 1 minute in Harris hematoxylin, 10 dips in tap water, 1 quick dip in 1% hydrochloric acid, and tap water to rinse off the acid. After inspection for slide quality, the slides were rinsed in 95% alcohol (10 dips, 3 times), 100% alcohol (10 dips, twice), and xylene (10 dips, twice), and then coverslipped. Fixed glass slides were stained in the following manner: 10 dips in reagent water, 8 seconds in Harris hematoxylin, 10 dips in reagent water, 10 dips in 95% alcohol (twice), 2 to 3 minutes in EA-50, 10 dips in 95% alcohol, 10 dips in 100% alcohol, and 10 dips in xylene (or until cleared). Coverslips were removed from cytology smears using xylene before immunostaining.
Cell block sections were prepared routinely as follows. The rinse (Roswell Park Memorial Institute 1640 medium [RPMI-1640] ; Invitrogen Life Technologies, Carlsbad, California) from the FNA or body fluid was centrifuged at 1500 revolutions per minute for 5 minutes. The cell pellet was combined with an equal amount of 10% formalin and 95% ethanol and then centrifuged at 1500 revolutions per minute for 10 minutes. The concentrated material then was folded in shark skin filter paper (Thermo Fisher, Waltham, Mass) and placed within a tissue cassette. The tissue cassette was placed in 10% formalin and processed as a cell block preparation in the histology laboratory. Paraffin-embedded cell block sections were stained with hematoxylin and eosin for morphologic evaluation and unstained sections were used for immunostaining purposes.
IPOX staining was performed using an anti-BRAF p.V600E (clone VE1, dilution 1:50; Spring Bioscience, Pleasanton, California) on a Ventana BenchMark ULTRA autostainer (Ventana Medical Systems/Roche, Tucson, Arizona). Briefly, the autostaining protocol consists of the following: antigen retrieval with a Tris-based buffer (Cell Conditioning Solution 1; Ventana Medical Systems/ Roche) for 64 minutes, peroxidase blocker, and primary antibody incubation for 48 minutes, followed with the OptiView DAB Detection Kit (Ventana Medical Systems/ Roche) for 16 minutes and finally counterstaining with hematoxylin and bluing reagent (Ventana Medical Systems/Roche). Only cytoplasmic staining (focal/diffuse) was considered as positive and scored as positive (strong: 2-31), equivocal (11), or negative (0). Only definitive tumor cells that were visualized on the immunostained smear and cell block section, were scored for BRAF p.V600E (VE1), and a minimum percentage staining cutoff value was not used as an adequacy criteria for the evaluation of IPOX. Staining was considered equivocal if there was very weak staining in the tumor cells (focal/diffuse cytoplasmic blush) or high background staining. The results of the BRAF p.V600E IPOX in cytology preparations were compared with the known BRAF p.V600E mutation status of the corresponding surgical pathology material and used to calculate the sensitivity and specificity. Cytology preparations with equivocal results were considered negative for the purposes of statistical analysis.
RESULTS
The current study included a total of 50 cases with cytologic diagnoses of PTC (29 cases), poorly differentiated carcinoma (10 cases), ATC (9 cases), and Hurthle cell carcinoma (2 cases) ( Table 1 ). The majority of cases were metastatic thyroid carcinomas with metastases to a lymph node (24 cases), soft tissue (5 cases), lung (1 case), kidney (1 case), and pleural fluid (1 case); 7 cases were recurrences in the thyroid bed, whereas the remaining 11 cases were FNAs of the thyroid gland (Table 1) . Of the 50 cases evaluated, 41 cases had BRAF mutation analysis by nextgeneration sequencing, 4 of which also underwent BRAF p.V600E (clone VE1) immunohistochemical evaluation on the corresponding surgical material. The remaining 9 cases underwent BRAF p.V600E (clone VE1) immunohistochemical staining on other surgical material from the same patient. The 2 cases of Hurthle cell carcinomas were from 2 different sites within the same patient and had an FNA diagnosis of "Hurthle cell neoplasm." The postresection surgical diagnosis was Hurthle cell carcinoma, for which BRAF p.V600E IPOX was performed to aid in excluding oncocytic PTC because BRAF mutations do not occur in Hurthle cell carcinomas. Of the 50 cases evaluated in the current study, 24 cases had a known positive BRAF p.V600E mutation by molecular and/or IPOX evaluation on the surgical pathology material, whereas 26 cases were negative. Twelve cases had paired cell block and smear preparations available for BRAF p.V600E IPOX evaluation; however 2 cases did not have definitive tumor cells on the direct smear after processing, and this precluded the evaluation of the smear preparation (Table 1) .
In 26 cases, FNA direct smear slides were tested for BRAF p.V600E IPOX, resulting in 16 positive cases, 4 negative cases, and 6 equivocal cases (due to high background staining and/or diffuse, weak cytoplasmic blushing in tumor cells). Of the smears, 16 cases were concordant with the BRAF p.V600E status of the corresponding surgical case (Fig. 1) . Four cases were discordant with false-positive staining in the smears in which the mutation analysis of the corresponding surgical case was negative for BRAF p. V600E (Fig. 2) . Six cases were noninformative due to equivocal staining, corresponded to 3 positive and 3 negative cases on the corresponding surgical case (Table 1) .
A total of 34 cases for which the clinical material included cell blocks were stained with BRAF p.V600E IPOX, which resulted in 17 positive cases, 16 negative cases, and 1 equivocal case (due to high background staining). Of the 34 FNA cell block preparations analyzed, 33 cases were concordant with the BRAF p.V600E status of the corresponding surgical case, whereas 1 case was deemed equivocal on the cytology (Table 1 ). The overall sensitivity of the cell block preparation was 94.4% with a specificity of 100%, whereas the overall sensitivity of the smears was 80% with a specificity of 63.6%.
DISCUSSION
To the best of our knowledge, therapeutic options for patients with advanced thyroid cancer of follicular origin remain limited, with only 2 drugs (sorafenib and lenvatinib) currently approved by the US Food and Drug Administration. [30] [31] [32] Although these drugs have demonstrated efficacy in patients with differentiated thyroid cancer, patients often require other choices for treatment either because they are no longer responding to these agents or as a result of adverse events. Therefore, there is a great need for additional therapeutic options. Clinical trials, such as the National Cancer Institute (NCI)-MATCH (Molecular
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Analysis for Therapy Choice) precision medicine clinical trial, focus on matching targeted therapy to specific molecular alterations. [33] [34] [35] This paradigm focuses on the molecular alterations driving tumorigenesis, and is irrespective of the exact underlying cancer diagnosis. BRAF p.V600E is a prime consideration for therapeutic matching because 2 BRAF inhibitors, vemurafenib and dabrafenib, approved by the US Food and Drug Administration, currently are available for the treatment of patients with metastatic melanoma. [36] [37] [38] [39] The increased availability of these agents and the notable clinical outcomes in patients with melanoma are driving an increasing number of clinical trials that are specific for patients with thyroid cancer (ClinicalTrials.gov identifiers NCT01286753, NCT01739764, NCT01723202, NCT02034110, NCT01709292, NCT03181100, and NCT01947023). To the best of our knowledge, studies performed to date in patients with thyroid cancer have shown response to the BRAF inhibitor vemurafenib, resulting in delayed tumor progression. 14, 16, 40 In patients with advanced thyroid cancer, targeted therapy using selective BRAF inhibitors is considered based on the presence of the BRAF p.V600E mutation. Although several studies have described BRAF p.V600E immunohistochemistry in surgical specimens of PTC as a rapid and cheaper alternative with a high sensitivity and specificity, [41] [42] [43] [44] [45] [46] molecular testing by mutational analysis remains the gold standard because IPOX rarely may fail to detect the BRAF p.V600E mutation. 47 In the current study cohort, the majority of the surgical cases had BRAF p.V600E mutation status determined by molecular testing using next-generation sequencing, with 9 cases that were evaluated by BRAF p.V600E (VE1) IPOX. At the study institution, BRAF p.V600E (VE1) IPOX on surgical pathology specimens demonstrates high concordance with BRAF p.V600E mutation status by molecular testing and often is used as a surrogate for the determination of BRAF p.V600E status when tissue is limited. FNA is widely used as the first-line approach to diagnosing clinically suspicious thyroid nodules, and although evaluation of BRAF p.V600E mutation by IPOX staining has been described in thyroid FNA cell blocks and liquidbased cytology, 28, [48] [49] [50] to the best of our knowledge there are relatively few studies concerning its utility when using FNA direct smears. 26 Although the translation of ancillary studies between surgical tissue (formalin-fixed, paraffinembedded) and cytologic preparations may appear insignificant, the preanalytic factors associated with a variety of cytologic substrates (eg, smears vs cell blocks vs liquidbased cytology, each using different fixatives, preservatives, and stains) require rigorous validation of the testing methodology before implementation in a clinical laboratory that impacts patient management decisions. 51, 52 A study by ) reported lower specificity and high false-positive rates, especially in the nonmalignant categories (overall sensitivity and specificity of 88.8% and 71.2%, respectively). 49 In contrast, a study of BRAF p.V600E IPOX by Wobker et al on cytology direct smears of PTC reported an overall sensitivity of 63.6% and a specificity of 58.3%. 26 Therefore, this finding highlights the need to validate the IPOX testing methodology in thyroid FNA samples across the spectrum of cytologic substrates used in a clinical setting. In the current study, we focused on validating the use of BRAF p.V600E IPOX staining in cytology smears and cell block preparations of thyroid FNA samples in which a malignant diagnosis was rendered on the cytology and/or subsequent surgical follow-up. The current study found a strong correlation of BRAF p.V600E IPOX staining on FNA cell blocks similar to the testing of surgical specimens, with an overall sensitivity of 94.4% and a specificity of 100%, with only 1 case being equivocal due to high background staining. This likely is due to the optimization of BRAF p.V600E IPOX for surgical tissue fixation and processing (formalin-fixed, paraffin-embedded), to which cell blocks also are subjected. However, false-positive staining in direct smears presented a challenge with regard to interpretation and lowered the overall sensitivity and specificity (80% and 63.6%, respectively). This was due to a combination of the cytoplasmic nature of the BRAF p.V600E IPOX and the tendency of cells to form 3-dimensional clumps on direct smears, thereby making it difficult to interpret "true-positive staining" versus "false-positive staining." As can be observed in Figures 1 and 2 , the true-positive staining (Fig.  1C) is difficult to distinguish from the false-positive staining (Fig. 2C ). This phenomenon also was described by Wobker et al, who reported that cell clusters in direct smears can trap the BRAF antibody, making interpretation of this antibody difficult. 26 Kim et al reported a similar occurrence in liquid-based cytology and attributed it to nonspecific staining of colloids, macrophages, and follicles containing colloids or stroma. 48 Rossi et al also reported that false-positive staining was noted on liquid-based preparations and attributed this to different fixatives and the staining of the whole cell on cytology specimens. 55 Collectively, the results of these studies, combined with our observations herein, highlight that BRAF p.V600E IPOX should be preferentially performed on cell block preparations when available. In cases in which there is no cell block available, mutational analysis for BRAF p.V600E performed using DNA extracted directly from smears would be the preferred alternative. [56] [57] [58] [59] [60] Immunostaining on direct smears of thyroid FNA samples is not recommended in isolation, without confirmatory molecular testing, due to the possibility of false-positive results.
Conclusions
BRAF p.V600E IPOX staining can be performed reliably on thyroid FNA cell block cytology preparations; however, false-positive results on direct smears limit their utility in the routine evaluation of BRAF p.V600E mutation status.
The results of the current study support the role of FNA assessment in thyroid carcinomas with the importance of cell block preparations, thus providing a tool for the preoperative expedited assessment of BRAF p.V600E mutation status.
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